

EDEN BIODESIGN AND HUMAN GENOME SCIENCES CO-PRESENT AT ASIA'S LEADING BIOPROCESSING CONFERENCE

Technology Transfer; The continuum of events that lead to a successful large scale production campaign

Liverpool, UK and Research Triangle Park, NC, USA; 20th October 2008: Dr. Crawford Brown, CEO, Eden Biodesign Ltd., UK and Lisa Cozza, Sr. Director, Manufacturing Alliances, Human Genome Sciences, Inc., USA will co-present a paper (presentation) on Technology Transfer at BioProcess International Asia Pacific on Tuesday 21st October.

Looking at scale-up and analytical comparability issues when transitioning mammalian cell culture processes from clinical scale to very large scale production, this presentation details some of the work that the two organisations undertook which culminated in the formal announcement of their collaboration in August 2008.

The conference has over 45 speakers from 12 countries presenting at this exciting 3-day event. In addition there will be five renowned industry commentators giving keynote speeches during the event.

Commenting on the paper that she will be co-presenting, Lisa Cozza, Sr. Director, Manufacturing Alliances, Human Genome Sciences, Inc said: "Tech transfer is not a discrete function. It is an evolving continuous process that drives the success of most clinical and commercial manufacturing programs. Our talk will highlight what we value in this process, how to mitigate risk, citing two real examples, and demonstrate how two companies will provide a seamless service to ensure success."

Dr. Crawford Brown, Chief Executive Officer, Eden Biodesign Ltd., UK added: "The seminal collaboration that we have with Human Genome Sciences has created a can-do environment as we work together to make a success of the partnership. The presentation will show how we built bridges across different cultures and geographic zones to create the environment for success."

Copies of the presentation will be available after the conference and will also be available on the Company website. Should you require an original copy please contact Liz Wyatt at De Facto Communications, email - l.wyatt@defacto.com

-ends-

For further information, please contact:

Liz Wyatt
De Facto Communications
+44 (0)20 7861 3043
l.wyatt@defacto.com

Notes to editors:

Eden Biodesign

Eden Biodesign is a successful international biopharmaceutical development and manufacturing services business that provides 'state of the art' development and manufacturing services to biotech clients across Europe, the USA and Asia. It promises all clients a committed service plus the knowledge and expertise to guide clients through process development, manufacturing, regulatory and technology transfer challenges.

The company uses the principles of 'Good Science' at every step of biopharmaceutical development to design programmes and processes that deliver clinically and commercially

valuable products, with an accomplished and attentive level of project management that clients need. For further information please visit www.edenbiodesign.com.

Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon® (albinterferon alfa-2b) for hepatitis C and LymphoStat-B® (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing. More information about HGS is available on the HGS web site at www.hgsi.com.